Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer
Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified
Explore 1 assets in Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Dren Bio
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05475925CT.gov A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer (this asset) | Dren Bio | P1/2 | CCC · 48 |
Other indications for Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Cutaneous Gamma-Delta T-Cell Lymphoma | — | P1/2 | CCC · 48 |
| Primary Cutaneous Aggressive Epidermotropic CD8+ T-Cell Lymphoma | — | P1/2 | CCC · 48 |
| T-Cell Large Granular Lymphocyte Leukemia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer in Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-humanmacaca-fascicularismacaca-mulatta-killer-cell-lectin-like-receptor-klrd1-human-monoclonal-dr-01-1-chain-disulfide-with-human-monoclonal-dr-01-chain-dimer-primary-cutaneous-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →